a Division of Arthritis & Rheumatic Diseases , Oregon Health & Sciences University , Portland , OR , USA.
b Department of Pharmacy , Oregon Health & Sciences University , Portland , OR , USA.
Expert Opin Biol Ther. 2016 Aug;16(8):1059-64. doi: 10.1080/14712598.2016.1205581.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA.
The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well.
While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.
中轴型脊柱关节炎（axSpA）是一种脊柱和骶髂（SI）关节的慢性炎症性疾病。axSpA 的范围包括强直性脊柱炎（AS）和非放射学中轴型脊柱关节炎（nr-axSpA）。有证据支持使用 TNFα 抑制剂（TNFi）治疗这些疾病，具有良好的疗效和可耐受的安全性。培塞利珠单抗（CZP）是一种抗 TNFα（TNFa）药物，有数据支持其用于 AS 和 nr-axSpA。
综述了 CZP 的药理学特性。回顾了 CZP 在 axSpA 中的使用和疗效数据。还讨论了 CZP 在 axSpA 患者中的生活质量结局和安全性概况。
虽然有几种生物制剂有改善 AS 结局的证据，但在疗效良好的 nr-axSpA 生物药物方面证据较少。CZP 在这两种疾病中均有改善临床疗效、患者报告结局和影像学结局的良好证据，且安全性可耐受。
